anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Chronic shoulder pain is the second most common musculoskeletal problem in the population with a prevalence ranging from 15% to 22%. Rotator cuff (RM) tears are one of the important pathophysiologic conditions leading to shoulder pain. Early treatment of RM tears is conservative and includes oral analgesics, non-steroidal anti-inflammatory drugs, corticosteroid injections if necessary and physiotherapy methods. Treatment of rotator sheath problems may be surgical and/or conservative depending on the indications. Surgical treatment is inevitable for partial tears and complete ruptures that do not respond to conservative treatment. After surgery, a good rehabilitation program is needed to increase the success of the surgical intervention, return to functional activities and improve the patient's quality of life. One of the most important problems for the patient, physician and physiotherapist in the rehabilitation program to be applied in this period is the immobilization period of 6 weeks. This is the recommended time for tissue healing. However, the negative effects of prolonged immobilization should not be forgotten. It is important to use early physiotherapy applications to prevent adhesions and reduce complications that may occur.

The Kinesio Taping® technique and Kinesio Tex® tape were developed in 1973 by Dr. Kenzo Kase, a Japanese chiropractor and acupuncturist. There is an increasing number of health professionals, including physicians and physiotherapists who deal with musculoskeletal diseases and lymphology, who apply this method to their patients all over the world. It is also widely used in the sports world, especially considering its ease of use and effects. It helps structures such as the musculoskeletal system, circulatory system and nervous system to return to normal function. It is a preferred method because these bands are easy to apply and patients can easily remove them. In the literature, there is no study examining the effects of kinesio tape application after rotator cuff repair.

Considering the effects of kinesio tape on pain and edema; we think that it will have positive results in the rehabilitation program applied after rotator cuff repair.
This study examined the impact of advance care planning (ACP) on the quality of life for patients with chronic kidney disease (CKD) at Komfo Anokye Teaching Hospital in Ghana. It specifically investigated patients' perspectives on their readiness for ACP. Utilizing a qualitative descriptive design, one-on-one interviews were conducted with CKD patients at the renal clinic, employing a semi-structured interview guide for thematic analysis of audio data. The findings revealed a gap in understanding among CKD patients, with participants acknowledging their vulnerability to renal failure, often linked to a medical history of diabetes and hypertension. Despite recognizing potential outcomes such as dialysis dependency or death, some patients retained hope for a cure, relying on faith. The initial kidney failure diagnosis induced shock and distress, leading many patients to prefer the comfort and familiarity of home-based care, including dialysis. Meanwhile, a minority favored hospital care to protect their children from psychological trauma. Most patients deemed legal preparations unnecessary, citing limited assets or a lack of concern for posthumous estate execution. These insights emphasize the necessity for targeted education and support in ACP to enhance patient outcomes in chronic kidney disease care and end-of-life planning.
Nontraumatic avascular necrosis of the femoral head(NANFH) is a common and refractory femoral head disease that causes bone death due to interruption of blood supply. Early clinical symptoms are atypical, such as hip pain and limited joint function. In the late stage, severe pain, shortening of the affected limb, claudication, and other serious symptoms are common, which se-riously affects the quality of life of patients. Therefore, it is of great significance to actively improve the clinical symptoms of NANFH to enhance the quality of life of patients. The pathogenesis of NANFH is complex, such as traumatic vascular circulatory disorders, the use of hormones or other drugs, alcoholism, and diabetes mellitus. These factors directly or indirectly lead to femoral head vascular damage, thrombosis, and coagulation system disorders, which reduce the blood supply to the acetabulum and femoral head, thus causing ischaemic death of the femoral head or even femoral head collapse. NANFH is mainly categorized as "bone impotence" and "bone paralysis" in traditional Chinese medicine(TCM). The treatment of NANFH with TCM has the characteristics and advantages of a long history, stable and reliable therapeutic effect, fewer adverse reactions, good patient tolerance, and high acceptance. Previous studies have shown that the promotion of angiogenesis is a key initiative in the prevention and treatment of NANFH, and TCM can promote fe-moral head angiogenesis by interfering with the expression of angiogenesis-related factors, which in turn can help to restore the blood supply of the femoral head and thus improve clinical symptoms of NANFH and prevent and treat NANFH. This article described the roles of blood supply interruption and angiogenesis in NANFH and the accumulated knowledge and experience of TCM in NANFH and summarized the role of angiogenesis-related factors in NANFH and the research progress on TCM intervention, so as to provide an idea for the subsequent research and a new basis for the clinical application of TCM in the treatment of NANFH.
<P>PROBLEM TO BE SOLVED: To provide a bill medical entry device for enabling even a person who has used a bill medical entry sheet being a paper medium to easily enter medical treatment fee in a bill medical entry sheet displayed on a picture.  <P>SOLUTION: This bill medical entry device acquires bill medical display data from a hard disk, and displays the image of a bill medical entry sheet on a display. When deciding that a certain region on the bill medical entry sheet displayed on the display has been selected by a mouse or the like, the bill medical entry device performs the input processing of a medical treatment fee for displaying a medical treatment fee which can be input to the region. When deciding that the input to the selected region has been ended, the bill medical entry device displays the input medical treatment fee on the bill medical entry sheet displayed on the display. Thus, it is possible to easily enter the medical treatment fee on the bill medical entry sheet displayed on the picture.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
This study pointed out that 3D surgico-anatomical models lead to more precise anatomical understanding compared to CT images in terms of detail perception. The 3D models of vascular patterns proves to be the optimal design according to the experts' evaluation with its teaching effects on surgical residents. The demonstration of the hepatic source vascular anatomy and corresponding vascular patterns may provide practically useful guides in decision making related to vascular detail during living donor liver transplantation.Model CT's were measured in order to verify 1:1 modelling and the printing the process was carried out with 3D printers of Mass Portal Pharaoh xd 20 with Eryone PLA 3D printer flament (2.2LBS)/Spool, White). Measurements of the anatomical structures were compared between the original CT images, and the CT images of the 3D model. The morphometric values such as inter-arterial distances, inter-venous distances and the distance between artery and vein were noted.
Hemophilia A and von Willebrand’s Disease (Type I): Desmopressin Acetate Injection 4 mcg/mL is administered as an intravenous infusion at a dose of 0.3 mcg Desmopressin Acetate Injection/kg body weight diluted in sterile physiological saline and infused slowly over 15 to 30 minutes. In adults and children weighing more than 10 kg, 50 mL of diluent is recommended; in children weighing 10 kg or less, 10 mL of diluent is recommended. Blood pressure and pulse should be monitored during infusion. If Desmopressin Acetate Injection 4 mcg/mL is used preoperatively, it should be administered 30 minutes prior to the scheduled procedure. 

The necessity for repeat administration of Desmopressin Acetate Injection or use of any blood products for hemostasis should be determined by laboratory response as well as the clinical condition of the patient. The tendency toward tachyphylaxis (lessening of response) with repeated administration given more frequently than every 48 hours should be considered in treating each patient.

Fluid restriction should be observed. (See WARNINGS, PRECAUTIONS, Pediatric Use and Geriatric Use.) 

Diabetes Insipidus: This formulation is administered subcutaneously or by direct intravenous injection. Desmopressin Acetate Injection 4 mcg/mL dosage must be determined for each patient and adjusted according to the pattern of response. Response should be estimated by two parameters: adequate duration of sleep and adequate, not excessive, water turnover. 

The usual dosage range in adults is 0.5 mL (2.0 mcg) to 1 mL (4.0 mcg) daily, administered intravenously or subcutaneously, usually in two divided doses. The morning and evening doses should be separately adjusted for an adequate diurnal rhythm of water turnover. For patients who have been controlled on intranasal Desmopressin Acetate Injection and who must be switched to the injection form, either because of poor intranasal absorption or because of the need for surgery, the comparable antidiuretic dose of the injection is about one-tenth the intranasal dose.

Fluid restriction should be observed. (See WARNINGS, PRECAUTIONS, Pediatric Use and Geriatric Use.) 

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.

Geriatric Use: This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. (See CLINICAL PHARMACOLOGY, Human Pharmacokinetics, CONTRAINDICATIONS, and PRECAUTIONS, Geriatric Use.)
Women with RIF received intralipid 20% (at a dose of 9mg/mL of the total blood volume, corresponding to 2 mL intralipid diluted at 20% in 250 mL normal saline) given over 1-2 hours on the day of oocyte retrieval. Dose is repeated on/the following day of a positive pregnancy test, followed by a final dose 2-3 weeks later when attending for pregnancy scan.
Patients in this arm of the trial carried out computerized online training drawn from the Feskits program (www.feskits.com), chosen to have attention, memory and executive function components. Specifically the sessions included the following exercises: sustained attention (4 minutes), attention/perception (5 minutes), working memory (8 minutes), auditory and visual memory (8 minutes), executive function (10 minutes), language (6 minutes), and games (4 minutes).
A recombinant immunotoxin plasmid targeting activated Th1 cells is constructed by gene recombination. A chemokine Rantes acts as a targeting molecule and an active fragment DT390 of diphtherotoxin functions as a toxin molecule in this plasmid. The method of producing the immunotoxin plasmid comprises the following steps: construction of a recombinant plasmid and preparation of an engineering bacterium transfected by the recombinant plasmid. The immunotoxin plasmid has specific targeting. It can induce specific immunity tolerance and thereby avoid non-selectively damage of all the T cells through targeting function of Rantes and specific attack on activated Th1 cells by DT390. It is especially suitable for the prevention and treatment of autoimmune disease and rejection reaction to organ transplantation. It can be also applied in the treatment of tumors.
Aging processes in the musculoskeletal system lead to functional impairments that restrict participation. Purpose: To assess differences in force and motor recruitment patterns of shoulder muscles between age groups to understand functional disorders. A cross-sectional study comparing thirty adults (20-64) and 30 older adults (\>65). Surface-electromyography (sEMG) of the middle deltoid, upper and lower trapezius, infraspinatus and serratus anterior muscles was recorded. Maximum isometric voluntary contraction (MIVC) was determined at 45° glenohumeral abduction. For the sEMG signal registration, concentric and excentric contraction with and without 1 kg and isometric contraction were requested. Participants abducted the arm from 0° up to an abduction angle of 135° for concentric and excentric contraction; and from 0º to 45º and remained there at 80% of the MIVC level while isometrically pushing against a handheld dynamometer. Differences in sEMG amplitudes (root mean square, RMS) of all contractions, but also onset latencies during concentric contraction of each muscle between age groups were analyzed. Statistical differences in strength (Adults\>Older adults;0.05) existed between groups. No significant differences in RMS values of dynamic contractions were detected, except for serratus anterior, but there were for isometric contraction of all muscles analyzed (Adults\>Older adults;0.05). The recruitment order varied between age groups, showing a general tendency towards delayed onset times in Older Adults, except for the upper trapezius muscle. Age differences in muscle recruitment patterns were found, which underscores the importance of developing musculoskeletal data to prevent and guide geriatric shoulder pathologies.
Cyclosporine nephropathy was detected in renal biopsies of 6 out of 60 (10%) rheumatoid arthritis patients after the average treatment duration of 19 months. Only one patient, out of these 6 patients, was treated with a dose ≤4 mg/kg/day. Serum creatinine improved in all but one patient after discontinuation of cyclosporine. The “maximal creatinine increase” appears to be a factor in predicting cyclosporine nephropathy.

There is a potential, as with other immunosuppressive agents, for an increase in the occurrence of malignant lymphomas with cyclosporine. It is not clear whether the risk with cyclosporine is greater than that in rheumatoid arthritis patients or in rheumatoid arthritis patients on cytotoxic treatment for this indication. Five cases of lymphoma were detected: four in a survey of approximately 2,300 patients treated with cyclosporine for rheumatoid arthritis, and another case of lymphoma was reported in a clinical trial. Although other tumors (12 skin cancers, 24 solid tumors of diverse types, and 1 multiple myeloma) were also reported in this survey, epidemiologic analyses did not support a relationship to cyclosporine other than for malignant lymphomas.

Patients should be thoroughly evaluated before and during Cyclosporine Capsules USP MODIFIED treatment for the development of malignancies. Moreover, use of Cyclosporine Capsules USP MODIFIED therapy with other immunosuppressive agents may induce an excessive immunosuppression which is known to increase the risk of malignancy.
Agent for external application to teeth for dental treatment to prevent tartar, eliminate caries and dissolve stains, consists at least partially of an aq. soln. obtd. by mixing (a) a soln. of an alkali(ne earth) hypochlorite and (b) a soln. of an amino cpd. (pref. EDTA, glycocoll, sarcosine, taurine, amidosulphuric acid, aminoethanol or urea) which is capable of forming water-sol. N-chloro- and N-dichloro cpds. which are non-irritant to the mucous membranes. Since the agent has limited stability, it is pref. freshly prepd. just before use by mixing the two component solns. It can be applied to the teeth by use as a mouth rinse, by directing a spray (pref. a pulsed spray) on to the teeth, or by applying in the form of a paste with a brush. When used instead of mechanical drilling prior to the application of tooth fillings, the agent has no adverse effects on healthy dental material (dentine or enamel).
PURPOSE: A composition containing sorghum is provided to normalize glycometabolism disorders, and to prevent and treat diabetes and various complications caused by diabetes. CONSTITUTION: A pharmaceutical composition for preventing or treating diabetes contains the following: 0.1-50 wt% of a sorghum extract prepared by water, alcohol including 1-4 carbon atoms, or a mixture thereof; and a derivative of the sorghum extract, or a pharmaceutically acceptable salt thereof as an active ingredient. The sorghum extract contains gentisic acid, p-hydroxybenzoic acid, syringic acid, vanillin, and hesperetin. Health functional food for preventing or treating diabetes contains the sorghum extract, a derivative or salt thereof, and sitologically acceptable food additives. The health functional food includes powder, granules, tablets, capsules, or drink. [Reference numerals] (AA) Group of active ingredient active ingredient isolated from sorghum
Participants will receive sequential doses of oral trametinib tablet 2 mg QD from Day 1 to Day 42 and IV durvalumab 10 mg/kg Q2W starting from Day 29 (Week 5) up to 12 months. Post-durvalumab treatment period, participants who developed PD and meet the criteria for re-administration, will receive durvalumab 10 mg/kg up to an additional 12 months.
Women between the ages of 18 and 45 are needed for a study that looks at the effect of calcium supplementation on bone health during pregnancy in black and white women. Study subjects will be divided into two groups. Each group will take 2 study supplements each day, the supplement will be calcium or placebo (a pill without calcium). The study involves five visits to the Children's Hospital of Oakland Research Institute; each visit will be 1-2 hours in length. There are 3 study visits during pregnancy and 2 in the first year after delivery. At each visit you will have your blood drawn and be asked questions about what you eat and what type of activities you do. At visit 16 and 36 weeks and 4 and 12 months postpartum you will have your bone density measured. You will be paid $240 for completing the study.
The study will be an open-label single-arm study to evaluate the safety and tolerability of Galvani's neuromodulation system. Participants with active rheumatoid arthritis (RA) will be implanted with the Galvani system and receive active stimulation for 12 weeks. The total study duration in the study for each participant is approximately 5 months, with a 4-week screening period, 4 weeks recovery from surgery and a 12-week 'treatment' period. The participants will return to the clinic on pre-defined days for follow-up visits during the trial period. At Days 42 and/or Day 56, if study participants are not responding to stimulation, stimulation parameters might be adapted. At the end of the study (Day-84), participants will enroll in a long-term follow-up study up to 5-years after enrollment in this study.
The invention relates to a preparation process of integration-type novel formulation of DACHENGQI decoction and a production method thereof. The effective components of the novel formulation are made from the following raw materials: by weight, 12 parts of Radix Et Rhizoma Rhei, 15 parts of Magnolia officinalis, 12 parts of Fructus Aurantii Immaturus (Citrus aurantium and/or Citrus sinensis), and 9 parts of mirabilite. The production method includes the steps of supersonic airstream pulverization, alcohol-water extraction, ultrasonic pulverization and extraction, water decoction and concentration, supersonic spray-drying, nano-scale grinding, high-pressure emulsion and homogenization and nanoparticle preparation. The production method integrates the advantageous of the nano-carrier combination technique, such as multi-component synergism and multi-target. The large-scale production can greatly reduce the production cost, greatly improve the product quality and enhance the target property and sustained/controlled-release property of drugs. The novel formulation is orally administrated or externally applied during four time periods respectively based on the midnight-noon tidal flow and human qi-blood flow rule. The novel formulation is also processed to membranes and transdermal delivery agents which are applied to different parts of human body respectively according to the midnight-noon tidal flow and human qi-blood flow rule and can be directly absorbed by the skin.
<P>PROBLEM TO BE SOLVED: To provide peptides exhibiting immunochemical reaction to antibodies against Epstein-Barr virus (EBV) which is human herpes virus, and monoclonal antibodies and anti-idiotypic antibodies against these peptides.  <P>SOLUTION: The invention relates to a peptide or fragment thereof which is immunochemically reactive with Epstein-Barr Virus (EBV) antibodies. A new monoclonal antibody directed to the peptide or fragment thereof is also part of the invention. The invention also relates to a method for the detection of EBV or anti-EBV antibodies in a test fluid and also to an immunochemical reagent comprising a peptide, a fragment or a polypeptide according to the invention and a test kit to be used when applying the detection methods. Detection of EBV in a test fluid or tissue specimen using antibodies, monoclonal and polyclonal, directed to the peptide, which have the characteristics of detecting both native and denatured intact, functional EBNA-1 protein is also part of the present invention.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Systemic chemotherapy with standard schemes without cisplatin, such as Gemcitabine, Vinorelbine, Paclitaxel or Pemetrexed. Thoracic cavity perfusion of cisplatin 30mg/m2 each time, twice a week for four times.
PURPOSE:To obtain a skin water repellent excellent in water repellency and persistence thereof and further in preventive effects on hand roughening without stickiness by blending a water repellent-treated aerosol silica with a silicone oil. CONSTITUTION:A skin water repellent is obtained by blending (A) a water repellent-treated aerosol silica prepared by hydrophobizing treatment of aerosol silica having preferably >=100m<2>/g specific surface area with, e.g. a trimethylsilylating agent and (B) a silicone oil. Both the ingredients are blended in amounts of preferably 1-40wt.% ingredient (A) and 30-99wt.% ingredient (B) expressed in terms of amounts after volatilizing volatile ingredients. The aforementioned water repellent is excellent in water repellency, especially persistence thereof and has dry touch without any stickiness or sense of incompatibility. Since water repellency-protecting effects are not lost even after continuing kitchen work for a long period, the objective skin water repellent useful as a sun oil or skin protective cream ointment, etc., for surfers or kitchen work, etc., is obtained.
The invention discloses a resveratrol analogue and a preparation method and application thereof to treatment of diseases related to aging and SIRTI enzyme activity. The resveratrol analogue disclosed by the invention has an eliminating effect on DPPH radical (DPPH.), superoxide anion radical (O2<.->), hydroxide anion radical (OH.) and nitrogen peroxide radical (OHOO.) and has excellent antioxidation activity. Some derivatives of the resveratrol analogue are SIRTI enzyme activating agents while others are excellent SIRT1 enzyme inhibitors.
A system and method for automatic assignment of medical codes to unformatted data. The system engine automatically assigns medic codes (ICD 9, ICD 10 and other versions) to unformatted or uncoded medical documents (medical notes, discharge summaries etc.). The system reads a document and then scans it for diagnoses associated with the medical codes. When diagnoses is identified, the system can also examine the language context in which the diagnosis appears. Using rules derived from syntactic and semantic usage, the system decides whether to apply and identified ICD code to the document being processed or not. The output is a set of medical codes and the corresponding diagnoses can then be stored in or applied to a number of different mediums.